Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00987220 · ClinicalTrials.gov registry record
Effect of Aricept on Biomarkers (Acetylcholine, sAPP Alpha) In Cerebrospinal Fluid
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 12
- Enrollment target
NCT00987220: Completed study, sponsored by Pfizer.
NCT00987220 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00987220 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
Study Summary
It is hypothesized that the acetylcholinesterase inhibitor, donepezil, will increase acute cerebrospinal fluid (CSF) actylcholine levels in healthy volunteers following a 5mg single dose oral administration.
Interventions
- DRUG Placebo
- DRUG donepezil (Aricept)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-02 |
What the finished NCT00987220 record still lists
NCT00987220 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00987220 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00987220 about?
NCT00987220 is a clinical study titled "Effect of Aricept on Biomarkers (Acetylcholine, sAPP Alpha) In Cerebrospinal Fluid". It is hypothesized that the acetylcholinesterase inhibitor, donepezil, will increase acute cerebrospinal fluid (CSF) actylcholine levels in healthy volunteers following a 5mg single dose oral administration.
What is the current status of trial NCT00987220?
This trial is currently completed. The enrollment target is 12 participants. The study started on 2009-10. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00987220?
The interventions under investigation include: Placebo (DRUG), donepezil (Aricept) (DRUG).
Who is sponsoring clinical trial NCT00987220?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia